ESMO Congress – Barcelona, 2019

By 24 septembre 2019Actualités, Event

Dr Philippe Cassier, Principal Investigator of NETRIS Pharma Phase 1 dose-escalation clinical trial on solid tumors, will present the results of the trial at ESMO Conference in Barcelona. The presentation entitled “A first-in-human, phase 1 trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors” is scheduled for September 29th, 2019 (CEST) in room “Malaga Auditorium (Hall 5)” during the “Proffered Paper – Developmental therapeutics” session at 4:42 pm.